Clear-cell renal cell carcinoma - A comprehensive review of agents used in the contemporary management of advanced/metastatic disease
Gkolfinopoulos, Stavros, Psyrri, Amanda, Bamias, Aristotelis
Published in Oncology Reviews (26.02.2021)
Published in Oncology Reviews (26.02.2021)
Get full text
Journal Article
Book Review
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study
Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Kostopoulos, Ioannis V, Syrigou, Rodanthi-Eleni, Eleutherakis-Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Tsitsilonis, Ourania E, Kastritis, Efstathios, Dimopoulos, Meletios A
Published in Haematologica (Roma) (01.08.2024)
Published in Haematologica (Roma) (01.08.2024)
Get full text
Journal Article
P901: DARATUMUMAB, IXAZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PRE‐TREATED WITH A LENALIDOMIDE‐BASED REGIMEN: FINAL OUTCOMES OF THE PHASE 2 DARIA STUDY
Terpos, Evangelos, Gavriatopoulou, Maria, Katodritou, Eirini, Hatjiharissi, Evdoxia, Dialoupi, Ioanna, Verrou, Evgenia, Manousou, Kyriaki, Gkolfinopoulos, Stavros, Migkou, Magdalini, Delimpasi, Sosana, Symeonidis, Argiris, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P928: OCULAR ADVERSE EVENTS AND FUNCTIONAL IMPACT IN TRANSPLANT INELIGIBLE, NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL
Terpos, Evangelos, Ntanasis‐Stathopoulos, Ioannis, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis‐Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
P884: BELANTAMAB MAFODOTIN PLUS LENALIDOMIDE AND DEXAMETHASONE IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: UPDATED RESULTS FROM THE PHASE 1/2 BELARD STUDY
Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis‐Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis‐Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
Beyond EGFR and ALK : targeting rare mutations in advanced non-small cell lung cancer
Gkolfinopoulos, Stavros, Mountzios, Giannis
Published in Annals of translational medicine (01.04.2018)
Published in Annals of translational medicine (01.04.2018)
Get full text
Journal Article
Development and Analytical Validation of a Reverse Transcription Droplet Digital PCR (RT-ddPCR) Assay for PD-L1 Transcripts in Circulating Tumor Cells
Strati, Areti, Zavridou, Martha, Economopoulou, Panagiota, Gkolfinopoulos, Stavros, Psyrri, Amanda, Lianidou, Evi
Published in Clinical chemistry (Baltimore, Md.) (01.04.2021)
Published in Clinical chemistry (Baltimore, Md.) (01.04.2021)
Get full text
Journal Article
Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial
Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis-Papaiakovou, Evangelos, Douvali, Maria, Gkolfinopoulos, Stavros, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial
Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis-Papaiakovou, Evangelos, Douvali, Maria, Gkolfinopoulos, Stavros, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in Blood (02.11.2023)
Published in Blood (02.11.2023)
Get full text
Journal Article
Safety and clinical activity of belantamab mafodotin plus lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: The phase 1/2, prospective, open-label, BelaRd study
Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide/dexamethasone from the phase 1/2 BelaRd study
Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Fotiou, Despina, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Kanellias, Nikolaos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs)
Economopoulou, Panagiota, Gavrielatou, Niki, Papaxoinis, George, Kotsantis, Ioannis, Pantazopoulos, Anastasios, Anastasiou, Maria, Kavourakis, George, Gkolfinopoulos, Stavros, Psyrri, Amanda
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
Economopoulou, Panagiota, Kotsantis, Ioannis, Papaxoinis, George, Gavrielatou, Niki, Anastasiou, Maria, Pantazopoulos, Anastasios, Kavourakis, George, Gkolfinopoulos, Stavros, Panayiotides, Ioannis, Delides, Alexandros, Psyrri, Amanda
Published in Oral oncology (01.12.2020)
Published in Oral oncology (01.12.2020)
Get full text
Journal Article
Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial
Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Gavriatopoulou, Maria, Malandrakis, Panagiotis, Fotiou, Despina, Kanellias, Nikolaos, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Terpos, Evangelos, Kastritis, Efstathios, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Kanellias, Nikolaos, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Dimopoulos, Meletios A.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Terpos, Evangelos, Gavriatopoulou, Maria, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Fotiou, Despina, Kanellias, Nikolaos, Migkou, Magdalini, Theodorakakou, Foteini, Spiliopoulou, Vasiliki, Syrigou, Rodanthi, Eleutherakis Papaiakovou, Evangelos, Gkolfinopoulos, Stavros, Manousou, Kyriaki, Kastritis, Efstathios, Dimopoulos, Meletios A.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article